BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 2021;:102927. [PMID: 34474172 DOI: 10.1016/j.autrev.2021.102927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Barzegar M, Mirmosayyeb O, Ebrahimi N, Bagherieh S, Afshari-safavi A, Hosseinabadi AM, Shaygannejad V, Asgari N. COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 2021. [DOI: 10.1016/j.msard.2021.103359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Baron F, Canti L, Ariën KK, Kemlin D, Desombere I, Gerbaux M, Pannus P, Beguin Y, Marchant A, Humblet-baron S. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Front Immunol 2022;13:827242. [DOI: 10.3389/fimmu.2022.827242] [Reference Citation Analysis]
3 James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, Sharma V. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(22)00210-9. [PMID: 35382972 DOI: 10.1016/j.dld.2022.03.005] [Reference Citation Analysis]
4 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2021:S0016-5085(21)03701-X. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Reference Citation Analysis]
5 Aringer M, Alarcón-riquelme ME, Clowse M, Pons-estel GJ, Vital EM, Dall’era M. A glimpse into the future of systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210867. [DOI: 10.1177/1759720x221086719] [Reference Citation Analysis]
6 Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, Costanzo G, Secci M, Usai G, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med 2021. [PMID: 34741188 DOI: 10.1007/s10238-021-00771-3] [Reference Citation Analysis]
7 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Farroni C, Picchianti-diamanti A, Aiello A, Nicastri E, Laganà B, Agrati C, Castilletti C, Meschi S, Colavita F, Cuzzi G, Casetti R, Grassi G, Petrone L, Vanini V, Salmi A, Repele F, Altera AMG, Maffongelli G, Corpolongo A, Salemi S, Di Rosa R, Nalli G, Sesti G, Vaia F, Puro V, Goletti D. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Front Immunol 2022;13:846753. [DOI: 10.3389/fimmu.2022.846753] [Reference Citation Analysis]
9 Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, Almpani F, Christidou A, Viazis N, Mantzaris GJ, Tsafaridou M, Karmiris K, Theodoropoulou A, Papathanasiou E, Zampeli E, Michopoulos S, Tigkas S, Michalopoulos G, Laoudi E, Karatzas P, Mylonas I, Kyriakos N, Liatsos C, Kafetzi T, Theocharis G, Taka S, Panagiotopoulou K, Koutroubakis IE, Bamias G. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflamm Bowel Dis 2022:izac068. [PMID: 35394529 DOI: 10.1093/ibd/izac068] [Reference Citation Analysis]
10 Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 2022. [PMID: 35503130 DOI: 10.1007/s00296-022-05136-x] [Reference Citation Analysis]
11 Feuchtenberger M, Kovacs MS, Eder A, Nigg A, Schäfer A. Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Rheumatol Int. [DOI: 10.1007/s00296-022-05123-2] [Reference Citation Analysis]
12 Cerna K, Duricova D, Lukas M, Machkova N, Hruba V, Mitrova K, Kubickova K, Kostrejova M, Teplan V, Vasatko M, Kastylova K, Lukas M. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Inflamm Bowel Dis 2021:izab301. [PMID: 34849919 DOI: 10.1093/ibd/izab301] [Reference Citation Analysis]
13 Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Mariotti EB, Corrà A, Aimo C, Quintarelli L, Verdelli A, Li Gobbi F, Antiga E, Caproni M. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? Front Med 2022;9:811829. [DOI: 10.3389/fmed.2022.811829] [Reference Citation Analysis]
14 Antolí A, Rocamora-blanch G, Framil M, Mas-bosch V, Navarro S, Bermudez C, Martinez-yelamos S, Dopico E, Calatayud L, Garcia-muñoz N, Hernández-benítez LH, Riera-mestre A, Bas J, Masuet-aumatell C, Rigo-bonnin R, Morandeira F, Solanich X. Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. Front Immunol 2022;13:895209. [DOI: 10.3389/fimmu.2022.895209] [Reference Citation Analysis]
15 Benucci M, Damiani A, Gobbi FL, Lari B, Grossi V, Infantino M, Manfredi M. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis. Immunol Res 2022. [PMID: 35543863 DOI: 10.1007/s12026-022-09283-y] [Reference Citation Analysis]
16 Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, Costanzo G, Secci M, Usai G, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med 2021. [PMID: 34741188 DOI: 10.1007/s10238-021-00771-3] [Reference Citation Analysis]
17 Zhao T, Shen J, Zhu Y, Tian X, Wen G, Wei Y, Xu B, Fu C, Xie Z, Xi Y, Li Z, Peng J, Wu Y, Tang X, Wan C, Pan L, Li Z, Qin D. Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series. Front Public Health 2022;10:875558. [DOI: 10.3389/fpubh.2022.875558] [Reference Citation Analysis]
18 Tavares ACFMG, de Melo AKG, Cruz VA, de Souza VA, de Carvalho JS, Machado KLLL, de Azevedo Valadares LD, Dos Reis Neto ET, de Rezende RPV, de Resende Guimarães MFB, Ferreira GA, de Sousa Braz A, de Abreu Vieira RMR, de Medeiros Pinheiro M, Ribeiro SLE, Bica BEGR, Baptista KL, da Costa IP, Marques CDL, Lopes MLL, Martinez JE, Giorgi RDN, da Mota LMH, da Rocha Loures MAA, Dos Santos Paiva E, Monticielo OA, Xavier RM, Kakehasi AM, Pileggi GCS. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol 2022;62:3. [PMID: 35039077 DOI: 10.1186/s42358-022-00234-7] [Reference Citation Analysis]